从资金流向上来看，当日动物保健板块主力资金净流出1543.66万元，游资资金净流入2447.27万元，散户 资金净流出903.61万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.73 | -3.85% | 7.66万 | 8230.61万 | | 838275 | 驱动力 | 10.80 | -2.26% | 1.55万 | 1676.03万 | | 002141 | 后丰控股 | 4.03 | -1.95% | 23.77万 | 9597.12万 | | 839729 | 永顺生物 | 10.69 | -1.02% | 2.74万 | 2915.24万 | | 603566 | 普莱柯 | 14.51 | -0.75% | 2.59万 | 3755.59万 | | 603718 | 海利生物 | 7.12 | -0.14% | 5.90万 | 4190.82万 | | 600195 | 中牧股份 | 7.41 | - ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 838275 | 驱动力 | 11.05 | -1.43% | 2.32万 | 2594.86万 | | 688098 | 申联生物 | 11.61 | -0.94% | 15.33万 | + 1.75亿 | | 002868 | *ST绿康 | 26.25 | -0.64% | 7593.6 | 1997.06万 | | 603718 | 海利生物 | 7.13 | 0.00% | ﻛ 8.72万 | 6188.92万 | | 600195 | 中牧股份 | 7.42 | 0.41% | 9.64万 | 7120.77万 | | 002688 | 金河生物 | 6.99 | 0.72% | 16.24万 | 1.13亿 | | 300871 | 回盛生物 | 22.43 | 1.04% | 6.39万 | 1.42亿 | | 600201 | 生物股份 | 8.23 | 1.11% | 21.56万 | 1.76亿 | | 300119 | 瑞普 ...

证券之星消息，9月10日动物保健板块较上一交易日下跌0.5%，永顺生物领跌。当日上证指数报收于 3812.22，上涨0.13%。深证成指报收于12557.68，上涨0.38%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 838275 | 驱动力 | 11.21 | 2.75% | 2.01万 | | 2220.08万 | | 002868 | *ST绿康 | 26.42 | 1.62% | 9434.18 | | 2478.03万 | | 002141 | 后丰控股 | 4.00 | 0.76% | 20.14万 | | 8035.94万 | | 600201 | 生物股份 | 8.14 | 0.37% | 11.24万 | | 9132.56万 | | 871970 | 大禹生物 | 10.75 | 0.00% | 7.13万 | | 7520.81万 | | 603718 | 海利生物 | 7.13 | -0.28% | 11.64万 | | ...

普莱柯所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：动物疫苗、禽流感药 物、知识产权、宠物经济、小盘等。 截至6月30日，普莱柯股东户数1.80万，较上期增加4.27%；人均流通股19234股，较上期减少4.09%。 2025年1月-6月，普莱柯实现营业收入5.59亿元，同比增长15.79%；归母净利润1.16亿元，同比增长 57.12%。 分红方面，普莱柯A股上市后累计派现10.57亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年6月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第七大流通股东，持股344.99万股，相比上期增加14.14万股。 责任编辑：小浪快报 9月8日，普莱柯盘中上涨2.01%，截至09:53，报14.74元/股，成交2765.57万元，换手率0.55%，总市值 51.01亿元。 资金流向方面，主力资金净流入102.68万元，特大单买入156.68万元，占比5.67%，卖出0.00元，占比 0.00%；大单买入474.59万元，占比17.16%，卖出528.59万元，占比19.11%。 普莱柯今年以来股价涨19.21% ...

2025年上半年，下游养殖行情整体较为低迷状态，叠加大型养殖集团普遍采取较为激进的成本管控策略， 动保行业竞争加剧。2025H1公司推向市场的创新产品猪伪狂犬病活疫苗（HN1201-R1株）、以新支流减 腺五联灭活疫苗为代表的腺病毒系列禽用联苗得到市场的初步认可，为公司贡献新的业绩增长点。分产品 看，2025H1公司生物制品收入4.01亿元，同比+13.17%，其中，猪用生物制品收入1.31亿元，同 比-11.49%，行业竞争加剧导致猪用疫苗板块短期承压；禽用生物制品收入2.59亿元，同比+30.01%，主要 是普莱柯（南京）的新生产基地全面投入使用，高致病性禽流感疫苗产能进一步释放，2025H1公司高致 病性禽流感疫苗收入同比增长近60%；反刍动物用生物制品收入168万元，同比+39.62%。2025H1公司化 学药品收入1.24亿元，同比+20.94%。 宠物板块表现亮眼，打开中长期成长空间 宠物板块，公司继续坚持"线下"与"线上"并重的原则，一方面通过开展各种营销活动、优选合作经销商等 措施对猫三联灭活疫苗在内的重点产品进行市场推广，一方面在线上积极探索利用各大新媒体平台以直播 或种草等方式对相关产品进 ...

Industry Overview - The 27th Asia Pet Expo attracted over 510,000 visitors, showcasing the robust growth of China's pet economy, with a market size projected to reach 811.4 billion yuan by 2025, growing at a compound annual growth rate (CAGR) of 25.4% from 2015 to 2023 [1] - The pet-related business market in China has expanded from 97.8 billion yuan in 2015 to 592.8 billion yuan in 2023, indicating a significant upward trend [1] Company Performance - The pet sector achieved revenue of 6.381 billion yuan in the first half of 2025, a year-on-year increase of 22.03%, with net profit reaching 660 million yuan, up 20.28% [1] - Leading company Guobao Pet reported revenue of 3.221 billion yuan and net profit of 378 million yuan, with growth rates of 32.72% and 22.55% respectively [2] - Zhongchong Co. followed closely with revenue of 2.432 billion yuan and net profit of 203 million yuan, marking a 42.56% increase in net profit, the highest in the industry [2] - Petty Co. experienced a decline in both revenue and net profit, reporting 728 million yuan and 79 million yuan, down 13.94% and 19.23% respectively, attributed to U.S. tariff policies affecting overseas orders [3] - Lusi Co. reported an 11.32% increase in revenue to 391 million yuan but a 12.07% decrease in net profit to 30.46 million yuan due to falling product prices [3] Market Trends - The pet economy is driven by a generational shift in consumer attitudes, with younger generations (90s and 00s) becoming the primary pet owners, leading to a growing "it economy" around pets [5] - The pet food market holds a 52.8% share, followed by pet medical services at 28.0%, with increasing penetration rates in pet diagnosis, training, insurance, and travel [5] - The average cost of pet medical services is rising due to advancements in medical technology and diversified drug supply [5] Regulatory Environment - Recent policies from the Ministry of Agriculture and Rural Affairs and the State Administration for Market Regulation have focused on establishing standards for the pet industry [6] - Local governments are incorporating pet industry development into their plans, with initiatives aimed at promoting collaboration across various sectors [6] Investment Activity - The pet industry has seen 634 financing events as of the first quarter of 2025, with online platforms being the most active [6] - The pet economy concept index has risen by 43.21% year-to-date, indicating strong interest from the capital market [7]

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.2% on September 4, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (code: 838275) with a closing price of 11.96, up 6.50% [1] - Dayu Biological (code: 871970) with a closing price of 10.04, up 3.40% [1] - Yongshun Biological (code: 839729) with a closing price of 10.39, up 2.26% [1] - Conversely, Shunlian Biological (code: 688098) saw a decline of 2.98%, closing at 11.40 [2] Trading Volume and Capital Flow - The total trading volume for the animal health sector showed a net outflow of 85.41 million yuan from institutional investors, while retail investors saw a net inflow of 74.17 million yuan [2] - The capital flow for individual stocks indicated significant movements, with Shunlian Biological experiencing a net outflow of 10.12 million yuan from institutional investors [3] Individual Stock Analysis - Shunlian Biological had a total trading volume of 131,200 shares, with a net inflow of 7.73 million yuan from retail investors [3] - Other stocks like Huisheng Biological (code: 300871) and ST Green Kang (code: 002868) also showed varied capital flows, with Huisheng experiencing a net outflow of 12.50 million yuan from speculative funds [3]

普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 普莱柯生物工程股份有限公司 二 O 二五年九月 普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 普莱柯生物工程股份有限公司 为维护投资者的合法权益，确保普莱柯生物工程股份有限公司（以下简称"公 司"）2025 年第一次临时股东大会的正常秩序和议事效率，根据《中华人民共和 国公司法》 《公司章程》 项权利。股东事先准备发言的，应当先向会务组登记。股东不得无故中断股东大 会议程要求发言。本次会议在进行表决时，股东及股东代表不可进行大会发言。 明。对于涉及公司商业秘密的提问，会议主持人或相关负责人将在保密的基础上 尽量说明。 普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 二、会议的表决 择现场投票和网络投票中的一种表决方式，如同一表决权出现重复投票的，以第 一次投票结果为准。 《公司股东大会议事规则》等有关规定，特制定本次股东 大会会议须知： 一、会议组织 人员安排，共同维护好会议秩序。 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场。对于影响本次会议秩序和损害其他股东合法权益 ...

普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 二 O 二五年九月 1 普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议资料 普莱柯生物工程股份有限公司 2025 年第一次临时股东大会会议须知 为维护投资者的合法权益，确保普莱柯生物工程股份有限公司（以下简称"公 司"）2025 年第一次临时股东大会的正常秩序和议事效率，根据《中华人民共和 国公司法》《公司章程》《公司股东大会议事规则》等有关规定，特制定本次股东 大会会议须知： 一、会议组织 1、公司负责本次会议的程序安排和会务工作，出席会议人员应当听从工作 人员安排，共同维护好会议秩序。 2、为保证本次会议的正常秩序，除出席会议的股东及股东代表、董事、监 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场。对于影响本次会议秩序和损害其他股东合法权益的行为，公司将按规定加 以制止。 3、出席本次会议的股东及股东代表应当按照公司《关于召开 2025 年第一次 临时股东大会的通知》要求，持相关证件办理签到手续。在大会主持人宣布现场 出席会 ...